

Subject Index

A

Acetaldehyde, 912
 Acetoacetyl-CoA synthetase, 50
 Acinar autoantibodies, 347
 Activated T-lymphocytes, 507, 792
 Acyl-CoA:cholesterol acyltransferase, 342
 Adenine nucleotides, 629
 Adenosine
 deaminase, 629
 myocardial insulin responsiveness, 842
 Adipocytes, 912, 1618
 Adjuvants, synergistic effects, 112
 Adoptive immunotherapy, 1305
 β -Adrenergic receptor, 1181, 1386
 Aggregating agents, 780, 1652
 Aging
 collagen browning and cross-linking, 867
 glucose intolerance, 119
 Alanine production, 237, 1559
 Aldose reductase
 inhibition, 359, 471, 558, 969, 1324
 neuropathy pathogenesis, 688
 retinopathy, 1658
 substance P, 488
 Allograft transplantation
 pancreatic endocrine cells, 383
 pancreatic islet cells, 1129
 Alloxan, 1015
 -induced diabetic rats, 1173, 1340
 American Indians, 622
 Amino acid
 glucogenic, 237
 glycosylated, 1144
 heart balance, 943
 infusion effects, 1365
 Amylase, 1173
 Angiopathy, 1260
 Angiotensin II, 1064
 Antigens
 class I, 209, 362, 796, 1411
 class II, 209, 482, 796, 1373, 1637
 islet cells, 1137
 64,000-M_r, 1419
 Antithrombin III, 1103
 Anti-asialo-GM1 antibody, 838
 Anti-immunoglobulin antibodies, 462
 Apolipoprotein B, 1234
 Arachidonate, enhanced availability, 429
 Arachidonic acid
 activator of protein kinase C, 4, 1453
 metabolites, 992
 Arginine
 β -endorphin effects, 1265
 insulin response, 723

Ascorbic acid, 359
 Atherosclerosis, 832, 1380
 ATP
 cerebral metabolism, 760
 -sensitive K⁺ channel, 495, 847
 Autoimmune thyroid disease, 317
 Autoimmunity, 257, 520, 1419
 cell-mediated, 873
 Autonomic nervous system
 abnormality, 446
 CSII effect on, 452
 Axonal transport of substance P, 488

B

Bacitracin, 800
 Bacterial killing, 544
 Basement membranes, 532
 BioBreeding (BB) rat. See Rats
 BB/W rats. See Rats
 Biosynthesis, HIT cells, 160, 1509
 Blood flow
 detection of vascular dysfunction, 292
 subcutaneous and insulin absorption, 694
 thermoregulation, 961
 Blood withdrawal, 327
 Bone
 calcium, 702
 γ -carboxyglutamic acid-containing protein, 702
 cell metabolism, 33
 formation and collagen production, 371
 hydroxyproline, 702
 marrow transplantation, 520
 mineral content, 8
 Breast-feeding, 1625
 Brittle diabetes, 81
 Butylated hydroxytoluene, 1505

C

Calcium
 antagonists, 936
 arachidonic acid effect, 1453
 cellular homeostasis alterations, 13
 phosphoinositide hydrolysis, 1478
 voltage-dependent channels, 847
 cAMP
 binding to protein kinase, 857
 phosphodiesterase activity, 717
 Canadian children, 1096
 Carbohydrate storage, 303

Cardiac
 function, 851
 L-carnitine effect, 1358
 myo-inositol effect, 1542
 ultrastructure, 936
 unresponsiveness, 1181
 Cardiac metabolism, 936
 Cardiomyopathy, 936, 1168
 L-Carnitine, 1358
 Cataractogenesis, 1505
 Catecholamines
 hydrochloride salt effect, 540
 low-density lipoprotein-receptor activity, effect on, 1386
 β -Cell, 260
 activation, 137
 cholecystokinin effects, 1432
 coupling increased, 908
 destruction
 interleukin 1, 916
 markers, 99
 marrow transfer, 252
 prevention of, 930
 progression from insulin, 1108
 reovirus infection, 362
 epinephrine effects, 65
 function assessment, 377
 glucose-induced depolarization, 495
 glucose-induced diabetes, 600
 granules, 194
 growth, 232
 insulin secretory responses altered, 137, 217
 interleukin 1 effects, 1311
 loss indicator, 723
 morphology, 89
 pancreatic
 ATP-sensitive K⁺ channels, 495
 glucose metabolism control, 1524
 secretory capacity, 81
 sulfonylureas, 1090
 parotidectomy, effect of, 441
 polarity, 616
 sensitivity, 223
 streptozocin-induced toxicity, 213
 survival, predictors of, 920
 Cell birth rate, 232
 Central nervous system and clonidine, 44
 Cerebral metabolism, 760
 Cheiroarthropathy, reduced lung volumes, 829
 Cholecystokinin, 13, 1432
 Cholesterol
 absorption, 342
 ester synthesis, 550
 insulin deficiency, 1151
 intensive treatment effect, 393

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136

February, 137-255

March, 257-365

April, 367-493

May, 495-665

June, 667-845

July, 847-1004

August, 1005-1156

September, 1157-1309

October, 1311-1448

November, 1449-1590

December, 1591-1726

This index covers all reading matter in Volume 37 of Diabetes except abstracts of papers presented at the 48th Annual Meeting of the American Diabetes Association.

SUBJECT INDEX 1988

Citric acid cycle, 89
 Clamps
 euglycemic, 303, 780, 787, 885
 euglycemic-hyperinsulinemic, 842, 1212, 1684
 glucose, 1025
 hyperglycemic, 1351
 Clonidine and hyperglycemia, 44
 Coxsackievirus B4 infection, 1419
 Collagen
 ascorbic acid, 359
 browning and aging, 867
 decreased production, 371
 glycosylated, 1144
 mesangial sclerosis, 1695
 type IV and basement membranes, 532
 Complications
 basement membranes, 532
 vascular dysfunction, 292
 Connective tissue, reduced lung volumes, 829
 Continuous subcutaneous insulin infusion (CSII)
 autonomic and somatosensory nerve function, 452
 counterregulatory hormone responses, 526
 Cori cycle, 154
 Coronary artery disease, 1595
 Cosegregation, 1068
 Counterregulatory hormone response, 81, 526, 901, 1531, 1608
 Crinophagy, 309
 Cross-linking and aging, 867
 CSII. See Continuous subcutaneous insulin infusion (CSII)
 CS-045, 1549
 Cyclohexamide, 1426
 Cyclophosphamide, 930, 1722
 Cyclosporin A, 873, 1049, 1305, 1574
 Cyclo(His-Pro), 1120
 Cytochrome P-450, 577
 Cytokines, 133
 Cytotoxicity, 133
 C-peptide
 concentrations, 1353
 kinetics, 223
 response to glucagon, 99
 secretion, 590, 920

D

Dawn phenomenon, 166
 Depolarization of glucose-induced β -cell, 495
 Diabetic foot, 714
 Diacylglycerol, activator of protein kinase C, 3, 499
 1,2-Diacylglycerol, 1168
 Diuresis, 949
 DNA damage, 1015

Dogs

adenosine and myocardial insulin responsiveness, 842
 amino acid infusion, 237
 β -Cell loss indicator, 723
 chronic diabetes effects, 943
 depancreatized, 600
 endogenous glucose production, 1025
 gluconeogenesis role, 749
 microvascular perfusion, 1715T
 myocardial metabolism, 943, 1684
 partially pancreatectomized, 723
 purified islets, 467
 Dopamine, 956
 DR1/4 patients, 926
 DR3/4 patients, 926
 Drug metabolism, cytochrome P-450, 577

E

Eicosanoids, 367
 ELISA. See Enzyme-linked immunosorbent assay (ELISA)
 Embryogenesis, 585, 637, 974
 Embryopathy, 974
 Endocrine growth, 232
 Endocrine Society, 1449
 Endogenous glucose production rate, 154, 1025
 Endogenous opioid peptides, 1253
 β -Endorphin, 1265
 Endothelium, 261
 Endothelial cells
 adherence of erythrocytes, 104
 factor VIII antigenicity, 482
 Endotoxin, synergistic effects, 112
 Environmental perturbants, 258
 Enzyme-linked immunosorbent assay (ELISA)
 islet cell antigens, 1137
 measurement of rat insulin, 321
 Enzyme inhibition, 89
 Epinephrine
 hypoglycemia, 901
 insulin absorption, 694
 insulin secretion, 65
 Epstein-Barr virus, 982
 Erythrocytes
 acylation of phosphatidylcholine, 142
 adherence to endothelial cells, 104
 charge and microalbuminuria, 745
 deformity, 471
 viscosity, 471
 Ethanol, 912
 Ethiopian immigrants, prevalence of diabetes, 824
 Ethnic groups
 Canadian children, 1096
 geographic patterns, 1113
 Israelis, 297
 Ethiopian immigrants, 824
 Japanese, 1068, 1633

Mexican Americans, 878

Pima Indians, 60, 622
 Etiology of diabetes, 257, 1328, 1625
 Etomoxir, 28
 Exocrine
 growth, 232
 secretion, 1173
 Exocytosis, 194
 Exon, human glucose-transporter gene, 657

F

Factor VIII, 482
 Familial diabetes. See Genetics
 Fasting, synergistic effects, 112
 Fatty acid synthesis, 50
 Feet. See Diabetic foot
 Fish oil, 1567
 Free fatty acids
 dawn phenomenon, 166
 early prandial insulin secretion, 736
 hypoglycemic effects of modifying drugs, 28
 insulin secretion, 1595
 insulin's antilipolytic effect, index of, 1271
 measurement, 1020
 Fruit flies, 847

G

Galactose cataracts, 1505
 Galanin, 1157
 Gangliosides, 645, 1340
 Gastric inhibitory polypeptide, 200
 Genes. See Genetics
 Genetics, 663
 analysis, 377, 569, 707
 β -Chain, 1633
 elements, 257
 human glucose-transporter gene, 657
 insulin Wakayama, 862
 Japanese, 1633
 mice, 707, 1163
 nucleotide substitution, 1068
 perinatal mortality, 1328
 organ-reactive autoantibodies, 1287
 susceptibility gene, 1005, 1438
 T-lymphocyte alterations, 1484
 Gestational diabetes, 377
 Glitazone. See Glyburide
 Glomerular
 barrier, 1202
 basement membrane, 532, 1144, 1324
 charge, 745
 deposits, 185
 filtration rate, 1044, 1641
 morphology, 38
 Na⁺-K⁺-ATPase, 558
 Glomeruli, 429
 Glomerulopathy, 38, 1202

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
 February, 137-255
 March, 257-365

April, 367-493
 May, 495-665
 June, 667-845

July, 847-1004
 August, 1005-1156
 September, 1157-1309

October, 1311-1448
 November, 1449-1590
 December, 1591-1726

SUBJECT INDEX 1988

- Glucagon
 β -Endorphin effects, 1265
 immunoreactivity, 31
 early prandial insulin secretion, 736
 growth hormone effects, 1678
 islet cell tumors, 1647
 secretion
 galanin effects, 1157
 pancreastatin effects, 281
 sodium butyrate effects, 1405
 Glucokinase, 563, 1524
 Gluconeogenesis, 749
 Glucose
 β -Endorphin effects, 1265
 cellular pathways, 421
 concentration, 1559
 control
 counterregulatory hormone response, 526
 pancreatic β -cells, 81
 insulin response, 286
 intolerance, age-related, 119
 intracellular free, 885
 measurement, 1020
 metabolism, 237, 563, 1226, 1426, 1470, 1524
 normalization of levels, 1689
 oxidation, 912, 916
 pantothenic acid uptake, 1335
 phosphoinositide hydrolysis, 1294
 recycling, 154
 thresholds, 901
 tolerance
 genetic analysis, 707
 impaired, 824, 1595
 intra-arterial test, 441
 myocardial uptake, 681
 toxicity, 681
 transport
 effect of phorbol esters, 499
 human glucose-transporter gene, 657, 1583
 inhibition of, 1217
 skeletal muscle glucose metabolism, 885
 turnover, taste-induced changes, 773
 usage, 563
 Glucose-induced insulin secretion, 217, 367, 398
 Glucose-induced diabetes, 600
 Glyburide, 857, 1090
 Glyceraldehyde phosphate, 997
 Glycogen
 metabolism, 262
 placental, 1665
 synthase, 436
 synthesis, 303, 499, 1559
 Glycolysis, 303
 Glycolytic intermediate, 997
 Glycosaminoglycans, 745, 1324
 Glycosylated
 hemoglobin
 level of and blood flow, 292
 oral glucose tolerance test, comparison, 60
 insulin, 787
 low-density lipoprotein, 550, 1652
 Golgi fractions, cAMP phosphodiesterase activity, 717
 Growth hormone, 166, 1678
 H
 HbA_{1c}. See Glycosylated hemoglobin
 Heart
 adenine nucleotide metabolism, 629
 L-carnitine treatment effects, 1358
 dysfunction, 936
 Heparan sulfate, 1324
 Heparin, 610, 1103
 Hepatic
 glucose
 output, 119
 production, 667, 1020, 1470, 1531
 uptake, 1559
 insulin secretion, 223
 surface receptors, 1316
 triglyceride lipase, 610
 Hepatocytes, 806, 1234, 1316
 Hexokinase, 563, 1524
 High-fat diet, 1397
 High-molecular-weight aggregates, 56
 HIT cells, insulin biosynthesis, 160, 1509
 HLA antigens, 796
 HLA-DQw3(TA10⁻), 926
 HLA-DR antigens, 99
 insulin-dependent diabetes, 1005
 Human
 fetal isletlike cell clusters, 1678
 fetal/neonatal development, 286
 glucose-transporter gene, 657
 insulin, 276
 insulinoma cells, 1279
 insulin-receptor gene, 1241
 islets, 413, 992
 mononuclear leukocytes, 1386
 See also Proinsulin
 Hydrochlorides, 540
 Hydroxyl radical scavengers, 1015
 Hyperglucagonemia, 44
 Hyperglycemia
 acquired, 1035
 brain striatum changes, 1120
 clonidine-induced, 44
 fasting, 673
 glucose-induced diabetes, 600
 L-carnitine treatment effects, 1358
 pain perception, 1253
 prandial, 736
 transient, 89
 Hyperimmunoglobulinemia A, 177
 Hyperinsulinemia, 1212
 Hyperlipidemia, 342, 1618
 Hypertension, 1595
 Hypertriglyceridemia, 832, 1271
 Hypoglycemia
 cerebral metabolism, 760
 counterregulatory hormone response, 526, 901, 1531, 1608
 gluconeogenesis role, 749
 -hypoinsulinemic effect, 1618
 insulin-induced, 81, 760, 1531
 Hypothalamus, regulatory peptides, 763
 I
 IDDM. See Insulin-dependent diabetes mellitus
 IgG proinsulin autoantibodies, 130
 Immune
 complexes, 185
 process, precursors of insulin, 130
 reactions, streptozocin-specific, 74
 regulation, 1009
 system role, 520
 Immunoglobulin A, elevated levels, 177, 185
 Immunology, 257, 662
 Incretin, 200
 Inflammatory mediators, 112
 Insulin
 absorption and epinephrine, 694
 action, 262, 540
 adipocyte metabolism, 912
 aggregates, 56, 1059
 alveolar macrophages, 544
 antibodies, 276, 920, 1049
 antipolytic effect, 1271
 autoantibodies, 317, 1392
 binding, bacitracin effect on, 800
 biosynthesis, 160, 309, 1226, 1509, 1678
 bone cell metabolism, 33
 cAMP phosphodiesterase activity, 717
 cephalic, 773
 clearance, 200, 1351
 covalent aggregates, 1059
 deficiency
 cholesterol, 1151
 macrophages, 544, 1076
 dimers, 56
 euglycemia, 723
 gene, 569
 glucoregulatory effect, 1271
 glucose-transporter gene expression, 1583
 glyccsylated, 787
 growth factor, 585
 human, 276
 hydrochloride salt effect, 540
 immunity, 172
 immunotherapy agents, 1188
 in vitro, 421, 780, 787
 in vivo, 421, 456, 780
 incretin effect, 200
 infusion
 counterregulatory hormone response, 526

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
 February, 137-255
 March, 257-365

April, 367-493
 May, 495-665
 June, 667-845

July, 847-1004
 August, 1005-1156
 September, 1157-1309

October, 1311-1448
 November, 1449-1590
 December, 1591-1726

SUBJECT INDEX 1988

- gluconeogenesis role, 749
intensive therapy, 393, 901
islet cell tumors, 1647
kinetics, 223
leucine metabolism, effect on, 512
mediator, 262
low-density lipoprotein-receptor activity, 1386
measurement, 1020
monomeric, 56
mutant allele, 1068
NPH, 172
oral administration, 246
pantothenic acid uptake, 1335
parotidectomy, effect of, 443
platelet function, 780
precursors of, 130
pulse, 1316
radioimmunoassay, 1392
receptors
alterations, 33
autophosphorylation, 1397
binding, 56, 262, 585, 1515
cephalic phase, 773
developmental regulation, 637
gene, 377, 1071, 1241
internalization, 806
kinase activity, 262, 1397
phosphorylation, 147
proreceptor cleavage failure, 653
pulses of insulin, 1316
structure defects, 982
resistance
cellular mechanisms, 677
glucose transport, 1217
hepatic glucose production, 1470
high-fat diet effects, 1397
in vitro, 421
in vivo, 421
leprechaunism, 982
lipid oxidation role, 678
maturity-onset diabetes of the young, 730
myocardial metabolism, 843, 943, 1684
non-insulin-dependent diabetes factor, 667, 1595
oral antidiabetic agent, 1549
phosphorylation, 147
proreceptor cleavage failure, 653
restriction-fragment-length polymorphism, 1071
site of, 670
summary, 672
retroviral antigen p73, 351
secretion
acute insulin responses, 723
arachidonate metabolites, 992
cAMP influence, 1478
cholecystokinin effects, 1432
cyclosporin effects, 1574
diminished, non-insulin-dependent diabetes factor, 667, 674
early prandial, 736
eicosanoids, 367
 β -Endorphin-induced effects, 1265
epinephrine effects, 65
fetal development, 286
galanin effects, 1157
glucose concentration changes, 309
glucose metabolism, 1226
increased, 200, 1351
integrated serum values, 590
interleukin 1, 916, 1311
intermediary metabolites, 997
maturity-onset diabetes of the young, 730
measuring, 223, 1195
mononuclear cells, 873
pancreastatin effects, 281
parotid glands, 441
phosphoinositides hydrolysis, 1294
protein kinase C, 3, 1453
residual significance, 81
response, 137, 217, 286
reversible impairment, 398
sulfonylureas, 847
tolbutamide effects, 816
sensitivity
chronic diabetes effect, 943
gestational diabetes, 377
non-insulin-dependent diabetes, 669
phorbol esters, 499
vascular smooth muscle cells, 1380
sodium butyrate effects, 1405
stimulated adipocyte lipogenesis, 912
subcutaneously injected, 694
treatment
cytochrome P-450, 577
IgG autoantibodies, 130
nephropathy, effects on, 1346
1,2-diacylglycerol, 1168
vanadate, mimetic effects, 1234
vasodilator action, 1064
Wakayama, 862, 1068
Insulinoma, 563, 1279
Insulin-dependent diabetes mellitus
activated T-lymphocytes, 507, 792
autonomic and somatosensory nerve function, 452
bone mineral content, 8
breast feeding, 1625
Canadian children, 1096
cardiac function, 851
 β -cell
destruction, 133, 930
survival, predictors of, 920
class I heavy-chain gene expression, 1411
cyclosporin A, 1049, 1574
etiology, 1328
geographic patterns, 1113
glycemic thresholds, 901
high-molecular-weight aggregates, 56
HLA, 1005
HLA-DQw3(TA10⁻), 926
IgG proinsulin antibodies, 130
insulinitis pathogenesis, 204
intensive therapy and low-density lipoproteins, 393
interleukin 1, 916
lung volumes reduced, 829
neonatal, 347
neuropathy, 476
oral administration of insulin, 246
prediction, 1591
recent-onset, antibodies, 462
remission, 1574
renal hemodynamics, 1044
stress and insulin absorption, 694
T-lymphocyte alterations, 1484
vascular dysfunction, 292
vitamin E supplementation, 1260
Insulin-like growth factor, 637, 1515, 1678, 1689, 1708
Insulinitis, 260
endogenous retrovirus, 1722
macrophage involvement, 989, 1053
pathogenesis of, 204
progression to β -cell destruction, 1108
protected rats, 1009
single-cell, 21
streptozocin induced, 1373
Intensive treatment and low-density lipoproteins, 393
Interferon- γ , 133, 209
Interleukin 1, 916, 1311
Interleukin 2
adoptive immunotherapy, 1305
islet cell cytotoxicity, 133
Intracellular
hormone degradation, 194
killing and alveolar macrophages, 544
Intrauterine environment, 622
Ion channels, 847
Islets
cell antibodies, 99, 347, 645, 664
cell antigens, 1137, 1287, 1587
cell tumors, 1647
cholecystokinin effects, 1432
destruction by cytokines, 133
endothelial cells, 482
function studies, 723
macrophage infiltration, 21
neogenesis, 891
phosphatidylcholine, 1489
protein kinase C characteristics, 3
regeneration, 334
secretion, 1316
See also Pancreatic islets
Islets of Langerhans
pancreatic polarity of β -Cell, 616
transplantation, 467
Isotope discrimination, 1025
Israel, prevalence of diabetes, 297
Ethiopian immigrants, 824

J

- Japan
abnormal insulinemia, 1068

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
February, 137-255
March, 257-365

April, 367-493
May, 495-665
June, 667-845

July, 847-1004
August, 1005-1156
September, 1157-1309

October, 1311-1448
November, 1449-1590
December, 1591-1726

SUBJECT INDEX 1988

genetics, 1633
Junctional coupling, 908

K

K⁺ channels, 495
Ketoacidosis, 1470
Ketogenesis, 50
Kidney
cells, bacitracin effect on, 800
transplantation, 1247
Kinase, 262

L

Lactate measurement, 1020, 1559
Laminin, basement membranes, 532
LDL. See Lipoprotein, low-density
Leg tissue, 1365
Leprechaunism, 982, 1515
Leucine
flux measurement, 1365
insulin effect on metabolism, 512
Linkage analysis, 569
Lipids, L-carnitine treatment effects, 1358
Lipoatrophic diabetes, 421
Lipogenesis, 50, 912
Lipoprotein
lipase, 610, 1076
low density
fish oil effect, 1567
metabolism, 393, 550
platelet aggregation, 1652
-receptor activity, 1386
Liposomes, 1123
Lipoxygenase, 65, 992
Liver Golgi fractions, 717
Lung volumes, 829
Lymphopenia, 327
Lymphoproliferation, 74
Lymphotoxin, islet cell cytotoxicity, 133
Lysosomes
bacitracin effects, 800
pancreatic islet function, 309

M

Macrophage
alveolar, 544
high-affinity receptor, 456
human, 550
infiltration in islets, 21
insulinitis development, 989, 1053
lipoprotein lipase, 1076
pathogenesis of insulin-dependent
diabetes, 1301
peritoneal, 456
Major histocompatibility complex (MHC)
class I antigens

heavy-chain gene expression, 1411
proteins, 362
class II antigens, 209, 482, 1373, 1637
reovirus infection, 362
susceptibility
gene, 1438
resistance to diabetes, 520
Mannoheptulose, 1426
Marrow transfer, 252
Mathematical modeling, 223, 1025
Maturity-onset diabetes of the young
(MODY), 730
MEDICA 16, 1618
Mesangial sclerosis, 1695
Mesenchyme, 891
Messenger RNA, human glucose-
transporter gene, 657
Mexican Americans, retinopathy, 878
Mice
β-cell granules morphometry, 194
coxsackievirus B4 infection, 1419
diet-induced obesity, 1163
embryos, binding to, 585
genetics, 707, 1287
glucose tolerance, 707
lipoprotein lipase, 1076
nonobese diabetic (NOD)
adoptive immunotherapy, 1305
autoantibodies, 1587
β-cell destruction, 930, 1108
insulin and retroviral antigen p73, 351
insulinitis, 204, 989, 1722
marrow transfer, 252
phospholipid metabolism,
T-lymphocyte clone, 1444
oral antidiabetic agent, 1549
pancreastatin effects, 281
transient hyperglycemia, 89
T-lymphocyte depletion, 1082
See also Streptozocin-induced diabetes
Microalbuminuria, 745
Microvascular
disease, 851
perfusion, 1715
Mixed meal, 436, 512
Monoclonal antibodies, 462, 1082, 1108,
1137
Mononuclear
cells, 832, 873
leukocytes, 1386
Morphine, 1253
Motor nerve conduction, 1247
Muscle
glucose metabolism, 667
skeletal
glycogen and mixed-meal, 436
phorbol esters effects, 499
myo-Inositol
myocardial lipids and cardiac function,
1542
neuroectodermal tissue, 974
neuropathy pathogenesis, 688
Myocardial
contractility, 851

glucose uptake, 842
lipids, 1168, 1542
metabolism, 943, 1684

N

Na⁺-K⁺ pump, insulin stimulation, 33
Na⁺-K⁺-ATPase, 558
neuropathy pathogenesis, 688
sciatic nerve abnormalities, 1340
Nanocapsules, 246
Nationwide Comprehensive Long-Range
Plan, 1449
Natural killer cells, 838
Neonatal diabetes, 347
Nephropathy
activated T-lymphocytes, 507
cardiac function, 851
erythrocyte charge, 736
insulin therapy effects, 1346
low-protein diet, 1641
mesangial sclerosis, 1695
Nerve conduction velocity, 969
Nesidioblastosis, 334
Neuroectodermal tissue, 974
Neuropathy
aldose reductase inhibition, 969
autonomic
abnormal thermoregulation, 961
diuresis, 949
development factors, 476
painful, 1253
pancreatic islet cell allotransplantation,
1129
pathogenesis, 688
phospholipid metabolism, 1703
pupillary unrest, 446
See also Polyneuropathy
Neuropeptide Y, 763
Nicotinic acid, additive hypoglycemic
effects, 28
Nonenzymatic glycosylation, 456, 532,
867, 1103, 1144
Nonimmunosuppressive immunomodulator,
1188
Nonobese diabetic mice. See Mice
Non-insulin-dependent diabetes mellitus
β-cell destruction markers, 99
day-long hypoinsulinemia, 590
familial, 377, 569
fish oil effect, 1567
genetic model, 398
glomerulopathy, 38
HLA antigens, 796
insulin resistance, 667, 1071, 1595
insulin secretion
diminished, 667
early prandial, 736
intrauterine environment, 622
Mexican Americans, 878
mixed-meal ingestion, 436
obesity, 154, 1163
pathogenesis, 679

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
February, 137-255
March, 257-365

April, 367-493
May, 495-665
June, 667-845

July, 847-1004
August, 1005-1156
September, 1157-1309

October, 1311-1448
November, 1449-1590
December, 1591-1726

SUBJECT INDEX 1988

proteinuria, 405, 1499
screening, 60
Norepinephrine, 1064
Normoglycemia, 467
5'-Nucleotidase, 629
Nucleotide substitution, 1068

O

Obesity
diet induced, 1163
increased rate of Cori cycle, 154
organ-reactive autoantibodies, 1287
taste-induced changes, 773
Opposum, bacitracin effect, 800
Oral antidiabetic agent, 1549
Oral glucose tolerance test, 60
Organ-reactive autoantibodies, 1287
Osteoblasts, insulin receptors, 33
Osteopenia
markers, 702
measurement, 8
Oxidation, 678, 1212, 1226

P

Painful neuropathy, 1253
Pancreas
bovine, 1137
ductal epithelium, 891
human, 286, 1137
macrophage subpopulations, 1301
murine, 1373
perfusion, 398
Pancreastatin, 281
Pancreatectomy, partial, 232, 723
Pancreatic
acini, 13
ductal epithelium, 891
endocrine cells, 383
islets
antigen, T-lymphocyte clone, 1444
cell allotransplantation and
neuropathy, 1129
cellular perfusion, 1715
class I heavy-chain gene expression,
1411
eicosanoids, 367
insulin production, 1226
insulin secretion, 992
interleukin 1, 916
isolation of, 413
liposomes, 1123
lysosomes, 309
neuropathy and allogeneic
transplantation, 1129
phosphatidylcholine, 1489
pregnancy, 908
proinsulin conversion, 1426
tolbutamide effects, 816
nonislet autoantibodies, 347
polarity, 616
remnants, 232

Pantothenic acid uptake, 1335
Parotid glands, 441
Paternal transmission, 1035
Peripheral glucose metabolism, 119
Perfusion, tolbutamide effects, 816
Perinatal mortality, 1328
Phagocytosis and alveolar macrophages,
544
Phorbol esters, effects on skeletal muscle,
499
Phosphatidylcholine, 142, 1489
Phosphodiesterase, cAMP activity, 717
Phosphofructokinase, 1524
Phosphoinositides
cholecystokinin effects, 1432
hydrolysis, 1294
insulin secretory response, 137
neuropathy pathogenesis, 688
tolbutamide effects, 816
Phospholipase A₂, 429, 1489
Phospholipase C, 429
Phospholipids
acylation, 142
1,2-diacylglycerol, 1168
metabolism, 1703
organization alterations, 104
Phosphorylation, 147, 262, 1703
Pima Indians, 60, 622
Plasma lipolytic activity, 610
Platelet
aggregation, 1652
insulin influence, 780
thromboxane A₂, 1260
Polyalkylcyanoacrylates, 246
Polygenic inheritance, 707
Polymerase chain reaction, 862
Polymorphism, 1068
restriction-fragment-length
polymorphisms, 377, 569, 1071
Polyneuropathy, 1000, 1247
Polyol pathway
abnormalities and ascorbic acid, 359
increased flux, 471
Poly(ADP-ribose) synthetase, 213
inhibitors, 1015
Pregnancy, 908, 1328, 1665, 1671
Prevalence
Israel, 297
Ethiopian immigrants, 824
Mexican Americans, 878
Pima Indians, 622
Prevention of diabetes, 327, 1009, 1188,
1591
Primary postbinding defects, 421
Professional vs. volunteer organization,
1449
Proinsulin
antibody, 276
conversion process, 1426
glucose-stimulated biosynthesis, 160,
1509
human immunogenicity, 276
IgG autoantibodies, 130
therapy, 276

Promoter region
human glucose-transporter gene, 657
human insulin-receptor gene, 1241
Proreceptor cleavage failure, 653
Prostaglandins, 429, 992, 1044
Protamines, 172
Protein degradation, 1665, 1671
Protein kinase C
insulin secretion, 3, 1453
skeletal muscle, 499
cAMP dependent, 857
Proteinuria
activated T-lymphocytes, 507
charge selectivity in glomerulopathy,
1202
effect on mortality, 1499
epidemiology of, 405
low-protein diet, 1641
Proteolysis, 512, 1365
Pupillary unrest, 446

R

Rabbit, femoral artery, 1064
Rats
additive hypoglycemic effects of drugs,
28
alloxan-induced diabetes, 1173, 1340
BB
alveolar macrophages, 544
class I heavy-chain gene expression,
1411
class II genes, 1637
diabetes prevention, 327, 1009, 1188
insulinitis and macrophages, 1053
recurrent autoimmune diabetes,
prevention of, 838
vascular smooth muscle cells, 1380
BB/E, macrophage subpopulations,
1301
BB/W
adenine nucleotide metabolism in
hearts, 629
immune system role, 520
cAMP phosphodiesterase activity, 717
L-carnitine treatment effects, 1358
cataractogenesis, 1505
β-cell secretory responses, 217
corpulent, 398
collagen production, 371
fasting, clonidine effects, 44
hepatic glucose uptake, 1559
hepatocytes, 1316
hypothalamic concentrations, 763
insulin
biosynthesis, 1509
glucose-induced secretion, 398
hydrochloride salt effect, 540
measurement, 321
receptor internalization, 806
stimulation of Na⁺-K⁺ pump, 33
insulinotropic effect, 441

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
February, 137-255
March, 257-365

April, 367-493
May, 495-665
June, 667-845

July, 847-1004
August, 1005-1156
September, 1157-1309

October, 1311-1448
November, 1449-1590
December, 1591-1726

SUBJECT INDEX 1988

- liver
 perfusion, 50
 sulfonylurea effect, 857
 major histocompatibility complex genes, 1438
 nephropathy, insulin therapy effects, 1346
 neuroectodermal tissue, 974
 neuropathy and allogeneic islet cell transplantation, 1129
 pancreatectomy, 232
 pancreatic
 acini, 13
 β -cells and sulfonylureas, 1090
 islets, 133, 413, 816, 908, 916, 1453, 1478
 perfused working hearts, 1335
 pregnancy, 908, 1665, 1671
 prostaglandin synthesis, 429
 reovirus infection, 362
 sand, 1618
 skeletal muscle, 499
 taste-induced changes, 773
 urinary bladder, 949
 See also Streptozocin-induced diabetes
 Receptors. See Insulin, receptors
 Recurrent autoimmune diabetes, 838
 Regulatory peptides, 763
 Renal hemodynamics, 1045
 Reovirus infection, 362
 Resistance to ischemic block conduction, 969, 1633
 Restriction-fragment-length polymorphisms (RFLPs), 377, 569, 1071, 1633
 Retinopathy, 878, 1658
 Retrovirus
 insulinitis, 1722
 retroviral antigen p73 and insulin, 351
- S**
 Saccharin ingestion and taste-induced changes, 773
 Sciatic nerve abnormalities, 1340
 Screening methods, 60
 Second-messenger molecules, 137
 Secretin, 1173
 Sensory nerve function after CSII, 452
 Serotonin, 956
 Serum factor, 1217
 Sialic acid, 745
 Silica particles, 21, 930
 Single-cell insulinitis, 21
 Skeletal muscle
 glucose transport, 885
 glycogen and mixed meal, 436
 phorbol ester effects, 499
 Sodium butyrate, 1405
 Somatostatin
 clonidine-induced hyperglycemia, 44
 galanin effects on secretion, 1157
 islet cell tumors,
 Somogyi phenomenon, 1608
 Sorbinil
 glomerular $\text{Na}^+ - \text{K}^+ - \text{ATPase}$, 558
 substance P, 488
 Sorbitol
 accumulation, 471
 neuroectodermal tissue, 974
 neuropathy pathogenesis, 688
 South African Indians, 796
 Splanchnic tissue, 237, 1365
 Sterol synthesis, 50
 Streptococcal preparation OK-432, 1188
 Streptozocin (STZ)
 β -cell damage, 213
 immunity to, 74
 low dose, 112
 toxicity, 1015
 Streptozocin-induced diabetes
 mice
 male inbred offspring, 1035
 single-cell insulinitis, 21
 T-lymphocyte depletion, 1082
 rats
 adenine nucleotide metabolism in hearts, 629
 β -adrenergic receptor, 1181
 aldose reductase inhibition effects, 969
 allotransplantation of pancreatic endocrine cells, 383
 cholesterol absorption, 342, 1151
 collagen production, 371
 cyclo(His-Pro) concentrations, 1120
 cytochrome P-450, 577
 1,2-diacylglycerol, 1168
 erythrocyte lipids, 142
 etomoxir effects, 28
 exocrine secretion, 1173
 glucose transport, 885
 immunoglobulin A levels, 177, 185
 insulin production, 1226
 ketone bodies and lipogenesis, 50
 myo-inositol effects, 1542
 nephropathy, insulin therapy effects, 1346
 neuropathy and allogeneic islet cell transplantation, 1129
 neuropeptide Y concentrations, 763
 nicotinic acid effects, 28
 oral administration of insulin, 246
 osteopenia markers, 702
 single-cell insulinitis, 21
 striatal biogenic amines, 956
 substance P, 488
 vascular permeability, 1689
 Syrian golden hamster, 334
 Streptozocin-induced insulinitis, 1373
 Striatal biogenic amines, 956
 Substance P, 488
 Succinate, 997
 Sugar phosphates, 760
 Sulfonylurea
 extrapancreatic actions, 857
 pancreatic β -cells, 1090
 receptors, 847
 Superoxide production by mononuclear cells, 832
 Suppressor/cytotoxic cells, 1484
 Sympathetic nervous system, 949, 1157
 Syrian golden hamster, 334
- T**
 Thermoregulation, 961
 Thromboxane B_2 , 780
 Thyrogastric antibodies, 99
 Thyroid. See Autoimmune thyroid disease
 Thyrotropin-releasing hormone, 1120
 Tolbutamide, 816, 857
 Transcutaneous oxygen tension, 714
 Triglycerides, 832, 1271
 L-Tryptophan, 956
 Tumor necrosis factor, 133
 Type I diabetes. See Insulin-dependent diabetes mellitus
 Type II diabetes. See Non-insulin-dependent diabetes mellitus
 Tyrosine kinase activity, 147
 T-lymphocytes
 activated, 507, 792
 alterations in insulin-dependent diabetes, 1484
 CD4^+ , 1444
 depletion, 1082
 Lyt2^+ , 930
 L3T4^+ , 204, 1108
 receptor, 1633
- U**
 Urea nitrogen pool, 1212
 Urinary
 albumin concentration and glomerulopathy, 38, 41
 bladder, 949
 C-peptide, 590, 1195
 excretion, 1044
 Utah Mormons, 569
- V**
 Vanadate, 1234
 Vascular
 dysfunction, 292
 permeability, 1689
 smooth muscle cells, 1380
 Vasodilator action, 1064
 Verapamil, 936
 Vitamin E supplementation, 1260
- W**
 Weight reduction and Cori cycle, 154

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
 February, 137-255
 March, 257-365

April, 367-493
 May, 495-665
 June, 667-845

July, 847-1004
 August, 1005-1156
 September, 1157-1309

October, 1311-1448
 November, 1449-1590
 December, 1591-1726

Author Index

A

Aaron, M., 237
 Abdul-Karim, F.W., 867
 Abe, N., 1181
 Abrass, C.K., 1695
 Achagiotis, C., 717
 Adler, J.H., 1618
 Afzal, N., 936
 Agharanya, J.C., 540
 Åhrén, B., 281
 Airey, C.M., 965
 Akiyama, N., 1168
 Akiyama, Y., 702
 Alani, S.M., 969
 Albisser, A.M., 526
 Aleck, K.A., 622
 Allen, N., 1103
 Almira, E.C., 1217
 Alvarez, I.M., 1217
 Alviggi, L., 1484
 Amano, K., 989, 1053
 Amatrua, J.M., 1234
 American Academy of Neurology, 1000
 American Diabetes Association, 1000
 Amiel, S.A., 901
 Anastasi, E., 462
 Anaya, P.A., 908
 Anderson, S.K., 1373
 Andersson, S., 286
 Andreani, D., 462, 1044
 Anfossi, G., 780
 Ansari, N.H., 1505
 Aprahamian, M., 246
 Arimori, S., 832
 Armitage, M., 1392
 Asakawa, H., 204
 Ashcroft, R.G., 362
 Ashford, M.J., 495
 Atkinson, M.A., 1587
 Aubert, D., 1096
 Auwerx, J., 8
 Awata, T., 1068

B

Baba, S., 1173
 Bacelj, A., 930
 Bach, J.-F., 873
 Baggio, B., 745
 Bailey, D., 1009
 Baird, H.R., 622, 1499
 Baird, J.D., 209, 1301
 Bak, J., 730
 Baker, J.R., Jr., 317

Ballard, D.J., 405
 Baquerizo, H., 133
 Barbosa, J.J., 1247
 Barker, C.F., 838
 Barrett, E.J., 237, 943, 1470
 Bar-Tana, J., 1618
 Bassas, L., 637
 Beard, J.C., 377, 723
 Beck-Nielsen, H., 436, 730
 Behnke, B., 1386
 Behr, S.R., 1076
 Bell, D., 829
 Bell, G.I., 657
 Belmonte, M.M., 1096
 Bending, J.J., 507, 1641
 Bendtzen, K., 916
 Benelli, C., 717
 Bennett, P.H., 622
 Bennett, T., 961
 Bergman, R.N., 1025
 Berti-Mattera, L.N., 1703
 Bertrand, J., 1279
 Bhathena, S.J., 398
 Bialer, M., 1059
 Bianchi, R., 1340
 Biggers, D.W., 749
 Blau, J., 297
 Blivet, M.-J., 421
 Bloom, S.R., 763
 Boden, G., 1212, 1708
 Bogardus, C., 154, 303
 Boitard, C., 873, 1049
 Bolognino, M., 1234
 Bone, A.J., 1301
 Bonner-Weir, S., 232, 482, 616, 1715
 Boquist, L., 89
 Boquist, S., 89
 Borg, L.A.H., 309
 Borsatti, A., 745
 Bottazzo, G.F., 99
 Bougnères, P.-F., 1049
 Bouillon, R., 8
 Boyd, A.E., III, 847
 Boyer, J., 142
 Bradley, B., 1444
 Brayman, K.L., 838
 Brockenbrough, J.S., 232
 Broderick, P.A., 956
 Brown, L.L., 1531
 Brown, R.A., 334
 Brownlee, M., 456
 Bruce, D.G., 736
 Brunengraber, H., 50
 Bunn, H.F., 1144
 Burant, C.F., 499

Burman, K.D., 317
 Burrin, J.M., 763
 Buse, M.G., 499

C

Cama, A., 982
 Campbell, I.L., 362, 645
 Campbell, S., 1096
 Campochiaro, P.A., 1658
 Canadian-European Randomized Control Trial Group, 1574
 Canavan, J.P., 1665, 1671
 Cancelli, A., 1044
 Capeau, J., 421
 Capogreco, C., 359
 Cardamone, I., 1044
 Cardoso, H., 763
 Caro, J.F., 1217
 Carr, R.K., 749, 1531
 Carraher, M.J., 622, 1499
 Casey, C., 1392
 Castaño, L., 1049
 Castellino, P., 1365
 Cavalot, F., 780
 Cerami, A., 456
 Chan, S.J., 862
 Chang, H., 28
 Chang, K., 1689
 Charlton, B., 930, 1108
 Chatterjee, N.K., 1419
 Chen, Y.-D.I., 1020
 Cherrington, A.D., 749, 1531
 Chisholm, D.J., 736
 Christensen, C.K., 452
 Christiansen, J.S., 452, 851
 Chu, C.-P., 405
 Chun, A.L., 949
 Cicerello, E., 745
 Cinotti, G.A., 1044
 Clarke, B.F., 829
 Cobelli, C., 223
 Cochrane, C., 1163
 Cohen, M.P., 297, 558, 824, 1324
 Coleman, D.L., 1287
 Colle, E., 792, 1096, 1411, 1438
 Collier, A., 829
 Colman, P.G., 645
 Colwell, J.A., 1449, 1652
 Comi, R., 1647
 Cook, D.L., 495
 Cook, D.S., 441
 Cooke, A., 209, 1301
 Cooksey, E.J., 829

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
 February, 137-255
 March, 257-365

April, 367-493
 May, 495-665
 June, 667-845

July, 847-1004
 August, 1005-1156
 September, 1157-1309

October, 1311-1448
 November, 1449-1590
 December, 1591-1726

AUTHOR INDEX 1988

Corsetti, L., 569
Couvreur, P., 246
Cozzolino, D., 1265
Craven, P.A., 429
Crepaldi, G., 745, 787
Crisa, L., 462

D

Damgé, C., 246
Dandona, P., 714, 912, 1260
Davidson, M.B., 166, 885
Dayer-Métroz, M.-D., 1082
DCCT Research Group, 476
Dean, B.M., 209
Debray-Sachs, M., 873
DeFronzo, R.A., 237, 667, 1365, 1470
De Leeuw, I.H., 471
De Luise, M.A., 33
Demidem, A., 1279
De Pablo, F., 637
Dequeker, J., 8
DeRubertis, F.R., 429
Desbuquois, B., 717
Dewar, R., 1096
Dhalla, K.S., 936
Dhalla, N.S., 936
Diabetes Epidemiology Research
International Group, 1113
Diaz, V.A., 1432, 1478
Dib, S.A., 462, 482
Digerness, S., 629
Di Mario, U., 462, 1044
DiSilvio, L., 119
Dodds, R.A., 1641
Dohm, G.L., 1217
Donahue, D.P., 749
Donahue, E.P., 1531
D'Onofrio, F., 1265
Dotta, F., 462
Drucker, D.J., 1647
Dudek, R.W., 891
Duguid, W.P., 334
Duner, E., 787
Dunning, B.E., 1157
Durand, A., 1279

E

Easom, R.A., 992, 1311
Eckel, R.H., 610
Edwards, D.L., 1509
Efendić, S., 281
Eichberg, J., 1703
Eisenbarth, G.S., 462, 482, 645, 662
Eizirik, D.L., 916
Elbein, S.C., 377, 569
El Haj, A.J., 1665
Emancipator, S.N., 867
Emanuelli, G., 780
Endemann, G., 50
England, J.D., 60

Epstein, S., 21
Ericsson, I., 89

F

Faber, O., 730
Fabris, M., 1340
Fahien, L.A., 997
Farr, A.G., 1373
Favreau, L.V., 577
Fedele, D., 787
Feinglos, M.N., 1163
Fernqvist, E., 694
Ferrannini, E., 237, 1470
Feutren, G., 873
Fiedorek, F.T., Jr., 707
Fineberg, N.S., 276
Fineberg, S.E., 276
Finegood, D.T., 1025
Finke, E.H., 413
Fiori, M.G., 1340
Fisher, E., 359
Fong, D., 878
Fonseca, V.A., 714
Forbes, P.M., 1015
Formby, B., 1305
Frank, B.H., 276, 800
Freed, L.E., 50
Frizzell, R.T., 749, 1531
Frohnert, P.P., 405
Fujino-Kurihara, H., 204
Fujita-Yamaguchi, Y., 1708
Fujiwara, H., 204
Fujiwara, T., 1549
Fuks, A., 1411, 1438
Fukuda, M., 81
Fukumoto, H., 657
Furcht, L.T., 532

G

Galloway, J.A., 276, 1195, 1351
Gambardella, S., 1044
Gambaro, G., 745
Ganguly, P.K., 936
Garlick, R.L., 1144
Garvey, W.T., 590
Gavin, J., 1689
Gavino, V.C., 50
Gay, E.C., 1625
Gaylarde, P.M., 714
Gelfand, R.A., 1365
Gepts, W., 1090
Gerald, M.C., 949
Gerich, J.E., 512, 1608
Gerling, I., 1419
Geusens, P., 8
Ghatei, M.A., 763
Gill, J.S., 763
Giroix, M.-H., 1226
Gisinger, C., 1260
Giugliano, D., 1265

Given, B.D., 1195
Gleichmann, H., 74
Glickman, M.G., 1365
Go, V.L.W., 200
Goetz, F.C., 1247
Goji, K., 1515
Gold, G., 160, 1509
Goldberg, I.J., 610
Goldfine, I.D., 1241
Goldgar, D., 569
Goldspink, D.F., 1665, 1671
Goldstein, D.E., 60
Goodner, C.J., 1316
Gorus, F.K., 1090
Goto, Y., 1188
Gotoh, M., 44
Green, A., 1217
Green, D.R., 749
Green, W.R., 1658
Greene, D.A., 688
Greer, M.K., 1637
Greiner, D.L., 520
Gretten, H., 1386
Gries, F.A., 130
Grodsky, G.M., 160, 1426, 1509
Groop, L.C., 99, 1470
Groop, P.-H., 99
Grose, M., 327
Gross, W.L., 321
Gulan, M., 526
Gundersen, H.J.G., 38, 446
Gunnarsson, R., 694
Gusberg, R., 237
Guttmann, R.D., 792, 920, 1411, 1438

H

Habener, J.F., 1405, 1647
Haffner, S.M., 878
Haftak, M., 1279
Hales, C.N., 495
Hall, C.R., 1015
Hallberg, A., 1123
Hamaoka, T., 204
Hamman, R.F., 1625
Hammond, M.G., 796
Hanafusa, T., 204
Handler, E.S., 257, 520
Hansen, C., 398
Hara, K., 702
Harker, M., 33
Harris, M.D., 166
Harrison, H.C., Jr., 1316
Harrison, L.C., 362, 926
Hartig, P.C., 213
Hasdai, D., 1253
Hashimoto, H., 1168
Haskins, K., 1444
Hattori, N., 1064
Haudenschild, C.C., 1380
Hawa, M.I., 119
Hayes, G.R., 147
Haymond, M.W., 512

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
February, 137-255
March, 257-365

April, 367-493
May, 495-665
June, 667-845

July, 847-1004
August, 1005-1156
September, 1157-1309

October, 1311-1448
November, 1449-1590
December, 1591-1726

AUTHOR INDEX 1988

Hazuda, H.P., 878
 Heffernan, S., 359
 Helderman, J.H., 600
 Hellerström, C., 1123, 1226
 Hendrick, G.K., 749, 1531
 Henningsen, P., 851
 Henriksen, O., 760
 Henry, R.R., 1071
 Hermann, H., 1405
 Hermansen, K., 452
 Heyliger, C.E., 1542
 Heyner, S., 585
 Hilsted, J., 760
 Hiramatsu, K., 832
 Hirshman, M., 56
 Hisatomi, A., 653, 1515
 Hoffman, B.B., 28
 Hoffman, J.M., 1489
 Hollenbeck, C., 1020
 Holowachuk, E.W., 1637
 Horikoshi, H., 1549
 Hors, J., 873
 Horton, E.S., 56
 Howard, B.V., 154
 Hreidarsson, A.B., 446
 Hufferd, S., 276
 Hughes, J.H., 992, 1311
 Humphrey, L.L., 405

I

Iguchi, A., 44
 Ikeda, T., 1064
 Ikegami, H., 81
 Imamura, T., 600
 Imura, H., 657, 702, 1583
 Inaba, M., 857
 Inman, L., 600
 Inoue, A., 857
 In't Veld, P.A., 1090
 Ionescu, E., 773
 Iori, E., 787
 Iriuchijima, T., 1120
 Ishibashi, O., 1515
 Ishida, H., 702
 Ishizaka, K., 351
 Issa-Chergui, B., 1411
 Itatsu, T., 1633
 Ito, M., 1633
 Ivarsson, S.-A., 347
 Iwamoto, Y., 1068
 Iwasaki, M., 1397, 1515
 Izui, S., 1082
 Izzo, M.J., 177, 185

J

Jack, I., 362
 Jackson, R.A., 119
 Jackson, T.K., 1234
 Jacob, R., 237, 943
 Jacobson, J.D., 838

Jacoby, J.H., 956
 Jaffe, S., 104
 Jakobsen, J., 452
 Jardieu, P., 351
 Jaskan, J.B., 119
 Jaworski, M.A., 1053
 Jeanrenaud, B., 773
 Jeng, C.-Y., 1020
 Jenkins, R.L., 629
 Jensen, K.E., 760
 Jeremy, J., 1260
 Jiao, S., 342
 Johnston, C., 1484
 Jorgensen, R.G., 292

K

Kahn, C.R., 1328
 Kakehi, T., 1583
 Kaku, K., 707
 Kalra, V.K., 104
 Kamura, H., 1633
 Kashiwagi, A., 1181
 Kaul, S., 1567
 Keen, H., 1641
 Keen, P., 488
 Kekow, J., 321
 Kennedy, W.R., 1247
 Khokher, M.A., 912
 Kida, Y., 1181
 Kiesel, U., 21
 Kihara, S., 342
 Kilo, C., 1689
 Kim, M.K., 1053, 1287
 Kimoto, M., 1082
 King, N.F., 1684
 Kissebah, A.H., 1567
 Kiyokawa, H., 1064
 Klass, D., 544
 Klein, R., 878
 Klein, R.L., 550, 1652
 Klepser, H., 558, 1324
 Klingensmith, G.J., 1625
 Klinkhammer, C., 74
 Knip, M., 286, 1678
 Knowler, W.C., 60, 622, 1499
 Knowles, B.B., 563
 Kobayashi, M., 653, 1397, 1515
 Kodama, M., 1181
 Koffler, M., 600
 Kolb, H., 21, 130
 Kolb-Bachofen, V., 21
 Kolterman, O.G., 436, 590
 Kondo, M., 862
 Kono, N., 204
 Korc, M., 13
 Kosaki, A., 1583
 Koskimies, S., 99
 Kraegen, E.W., 736
 Kraemer, F.B., 1076
 Krisch, K., 1137
 Kristoffersen, I., 452
 Krolewski, A.S., 1328

Krone, W., 1386
 Kubo, M., 342
 Kudlacz, E.M., 949
 Kuff, E.L., 351
 Kuglin, B., 130
 Kuhn, C.M., 1163
 Kumahara, Y., 81
 Kumar, D., 104
 Kuzuya, H., 1583
 Kuzuya, T., 1068

L

Lacy, D.B., 749, 1531
 Lacy, P.E., 112, 413, 992
 Lafferty, K., 1444
 Lang, F., 873
 Lapolla, A., 787
 Lamer, J., 262
 Larsen, S., 760
 Larson, D.M., 1380
 Lattimer, S.A., 688
 Law, W.R., 842, 1684
 Lawrence, I.E., Jr., 891
 Laychock, S.G., 1489
 Leahy, J.L., 217
 LeBon, T.R., 1708
 LeDoux, S.P., 213, 1015
 Lee, K.-U., 989, 1053
 Lee, Y.C., 763
 Legendre, C.M., 792
 Leiter, E.H., 252, 351, 1287
 Leonora, J., 441
 Le Petit-Thévenin, J., 142
 Lernmark, Å., 347
 Leslie, R.D.G., 1484
 Lesniak, M.A., 637
 Leutz, D.W., 1684
 Lezotte, D.C., 1625
 Lillioja, S., 154
 Linde, B., 694
 Lindskog, S., 281
 Little, R.R., 60
 Llewellyn, G., 714
 Lobo-Yeo, A., 507
 Lockwood, D.H., 147
 Logothetopoulos, J., 1009
 Lomeo, F., 912
 Lopaschuk, G.D., 1335
 Lopes-Virella, M.F., 550, 1652
 Lopez, D.R., 1151
 Lopez, S., 717
 Louard, R.J., 1365
 Loveless, R., 1392
 Lukes, Y.G., 317
 Luzi, L., 1470
 Lydyard, P.M., 209
 Lyons, T.J., 550

M

MacDonald, I.A., 961
 MacDonald, M.J., 997

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
 February, 137-255
 March, 257-365

April, 367-493
 May, 495-665
 June, 667-845

July, 847-1004
 August, 1005-1156
 September, 1157-1309

October, 1311-1448
 November, 1449-1590
 December, 1591-1726

AUTHOR INDEX 1988

Maclaren, N.K., 662, 1587, 1591
 Maddux, B.A., 1241
 Magré, J., 421
 Maislos, M., 1059
 Malaisse, W.J., 1226
 Mamula, P.W., 1241
 Mandarino, L.J., 436
 Mandel, T.E., 930, 1108
 Mannschreck, J.W., 1373
 Marcus-Samuels, B., 982
 Marini, P., 1340
 Markmann, J.F., 838
 Marliiss, E.B., 327
 Marner, B., 347
 Martin, D.R., 1637
 Marzaro, G., 745
 Massucco, P., 780
 Mastro Simone, S., 745
 Matschinsky, F.M., 563, 974, 1524
 Matsubara, K., 342
 Matsuda, A., 1068
 Matsuzawa, Y., 342
 Matthews, D.M., 829
 Mattioli, L., 292
 Mattson, B.A., 585
 Maugendre, D., 873
 May, E.E., 1658
 Mayer, E.J., 1625
 McArthur, R.G., 1287
 McClain, D.A., 806, 1071
 McCubbin, J.A., 1163
 McDaniel, H.G., 629
 McDaniel, M.L., 992, 1311
 McDonald, A.R., 1241
 McHardy, G.J.R., 829
 McKenzie, E.M., 60
 McLane, M.P., 842, 1684
 McLennan, S., 359
 McNamara, D.J., 1151
 McNeill, J.H., 1358, 1542
 Mead, P.M., 1059
 Mehta, J.G., 1053
 Melmed, R.N., 1253
 Melton, L.J., III, 405
 Meri, S., 99
 Merlini, S., 1340
 Metz, S.A., 3, 65, 1453
 Michaelis, O.E., IV, 398
 Michel, C., 246
 Miettinen, A., 99
 Mikhailidis, D., 1260
 Miller, L.L., 177, 185
 Miller, N., 1305
 Millward, B.A., 1484
 Misbin, R.I., 1217
 Miyagawa, J.-I., 204
 Miyano, M., 862
 Miyazaki, A., 204
 Mogensen, C.E., 452, 851
 Mojsos, S., 1647
 Moncayo, R., 1137
 Monnier, V.M., 867
 Moore, W.V., 292
 Mordes, J.P., 257, 520

Mori, M., 1120
 Morii, H., 857
 Morishima, Y., 1633
 Moriuchi, S., 702
 Motala, A.A., 796
 Mott, D.M., 154, 303
 Mraz, G., 926
 Mularoni, E., 780
 Müller-Ruchholtz, W., 321
 Mussini, E., 1340
 Myers, B.D., 1202

N

Naegele, H., 1386
 Nagamatsu, S., 1426
 Naimark, D., 544
 Najafi, H., 1524
 Najarian, J.S., 1247
 Naji, A., 838
 Nakajima, H., 204
 Nakamura, T., 342, 1173
 Nakamura, Y., 1202
 Nakano, K., 520
 Nanjo, K., 862
 Nathaniel, V., 1129
 Navarro, X., 1247
 Nayak, R.C., 645
 Nejman, C., 1419
 Neli, L.J., 172
 Nelson, R.G., 1499
 Nielsen, O.H., 730
 Niewoehner, C.B., 1559
 Nijs, J., 8
 Nilsson, K.O., 347
 Nishimura, H., 1583
 Nishio, Y., 1181
 Nishizawa, Y., 857
 Nissen, S.L., 512
 Nobili, O., 142
 Nobunaga, T., 1188
 Norlund, L., 194
 Norlund, R., 194
 Noto, Y., 1064
 Nuovo, J.A., 317
 Nuttall, F.Q., 1559

O

O'Brien, P.C., 200
 O'Fallon, W.M., 405
 Ogawa, K., 1168
 Ohki, A., 1173
 Okabayashi, Y., 1173
 Okamoto, M., 1583
 Okumura, K., 1168
 Okuno, S., 857
 Olack, B.J., 413
 Olefsky, J.M., 590, 806, 1071
 Omar, M.A.K., 796
 O'Neill, S.J., 544
 Ong, R.L., 629

Ono, S.J., 1411, 1438
 Østerby, R., 38
 Otonkoski, T., 286, 1678
 Otsuki, M., 1173
 Owen, O.E., 1212
 Oya, K., 1188

P

Pacini, G., 223
 Pak, C.Y., 1053, 1287
 Palumbo, P.J., 405
 Panner, B.J., 185
 Parker, J.C., 1524
 Parlow, A.F., 1531
 Parrish, S.W., 629
 Parsons, J.A., 908
 Pasquarello, T., 1137
 Paterniti, J.R., Jr., 610
 Patterson, J.K., 878
 Patterson, M.C., 429
 Patton, N.J., 213, 1015
 Pedersen, O., 730
 Pehling, G., 512
 Perlman, K., 526
 Permutt, M.A., 377, 569, 707
 Petersen, J., 1346
 Peterson, C.M., 1305
 Peterson, C.V., 1695
 Pettitt, D.J., 63, 622, 1499
 Pfeiffer, E.F., 1137
 Philippe, J., 1405, 1647
 Picard, J., 421
 Pierce, G.N., 936
 Pipeleers, D.G., 1090
 Polak, J.M., 763
 Poli, T., 787
 Polonsky, K.S., 1195, 1351
 Popowa, P., 74
 Portas, M., 1444
 Porte, D., Jr., 723
 Portha, B., 1226
 Poussier, P., 920
 Powell, A.M., 398
 Powers, A.C., 1405, 1647
 Price, D.E., 969
 Prince, D., 600
 Proietto, J., 773
 Province, M., 707
 Pugh, J.A., 878
 Pugliese, F., 1044
 Pukel, C., 133
 Pyke, D.A., 1484

Q

Qian, R.-L., 160

R

Rabinovitch, A., 133
 Rabkin, R., 800, 1346

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
 February, 137-255
 March, 257-365

April, 367-493
 May, 495-665
 June, 667-845

July, 847-1004
 August, 1005-1156
 September, 1157-1309

October, 1311-1448
 November, 1449-1590
 December, 1591-1726

AUTHOR INDEX 1988

Rafaelovsky, M., 297
 Rajotte, R.V., 467
 Raskin, P., 393
 Rathbun, M.J., 276
 Raugi, G.J., 1695
 Raymond, R.M., 842, 1684
 Raz, I., 1253
 Reaven, G.M., 28, 1020, 1595
 Recant, L., 398
 Reger, L.A., 532
 Renold, A.E., 1082
 Reynet, C., 421
 Ricordi, C., 413
 Rillaerts, E.G., 471
 Rivest, R.W., 773
 Rizza, R.A., 200, 512
 Robbins, D.C., 56, 1059
 Robertson, R.P., 1, 367
 Robinson, J., 1665
 Robinson, J.P., 488
 Rodrigues, B., 1358
 Rogers, D., 1689
 Rohner-Jeanrenaud, F., 773
 Roncari, D.A.K., 1287
 Rose-Kahn, G., 1618
 Rosenberg, C.S., 166
 Rosenberg, L., 334
 Rosenblum, I.Y., 585
 Rosenstock, J., 393
 Roshania, R.D., 119
 Ross, G.R., 359
 Ross, J., 1346
 Rossini, A.A., 257, 520, 662
 Roth, J., 637
 Rowold, E., 1689
 Rubenstein, A.H., 590, 1195, 1351
 Rue, P., 1195
 Rusecki, Y., 297, 824
 Russo, L., 292

S

Saeki, Y., 1181
 Sai, P., 873
 Saito, H., 1633
 Sakamoto, N., 44
 Salhanick, A.I., 1234
 Salvatore, T., 1265
 Samols, E., 1715
 Sandler, S., 916, 1123
 Sanke, T., 862
 Sarkany, I., 714
 Sasaoka, T., 653, 1397, 1515
 Satake, T., 1168
 Satin, L.S., 495
 Satoh, J., 1188
 Savitz, D.A., 1625
 Scharp, D.W., 413, 992
 Schectman, G., 1567
 Schenk, E.A., 185
 Schenkman, J.B., 577

Schernthaner, G., 1260
 Schiffrin, A., 792, 920
 Schmitz, A., 38, 452
 Schmitz, O., 730
 Schnell Landström, A.H., 309
 Schöni, M.H., 13
 Schuit, F.C., 1090
 Schwartz, R.G., 943
 Scott, A.R., 961
 Seedat, M.A., 796
 Seemayer, T.A., 327, 1411, 1438
 Segall, M., 1005
 Seino, S., 657
 Seino, Yo., 702
 Seino, Yu., 657, 702, 1583
 Sell, D.R., 867
 Seltzer, Z., 1253
 Sener, A., 1226
 Serradas, P., 1226
 Serrano, J., 637
 Serreze, D.V., 252, 351
 Service, F.J., 200, 512
 Shapiro, E.T., 1195, 1351
 Sheridan, J.D., 908
 Sherman, W.R., 1689
 Sherwin, R.S., 901
 Shigeta, Y., 653, 1181, 1397, 1515
 Shima, K., 81
 Shimizu, T., 653, 1524
 Shintani, S., 1188
 Shultz, L.D., 252
 Shumak, K., 1009
 Shuster, L.T., 200
 Siemiatycki, J., 1096
 Sim, B.M., 119
 Sima, A.A.F., 544, 688, 1129
 Simell, O., 286, 1678
 Simonson, D.C., 901
 Singal, P.K., 936
 Skau, K.A., 949
 Skolnick, M., 569
 Smith, D., 237
 Smith, R.M., 585
 Sole, M., 526
 Sorenson, R.L., 908, 1658
 Sowell, M.O., 499
 Spanheimer, R.G., 371
 Sparks, C.E., 1234
 Sparks, J.D., 1234
 Speiser, P., 1260
 Spiro, R.G., 1144
 Spradlin, C.T., 276
 Srivastava, S.K., 1505
 Stagner, J.I., 1715
 Steel, J.H., 763
 Steele, E.J., 1035
 Steiner, D.F., 862
 Steiner, L., 610
 Stern, E., 297, 824
 Stern, M.P., 878
 Stevenson, H.C., 550
 Stevenson, R.W., 749, 1531
 Stirati, G., 1044

Storlien, L.H., 736
 Strandell, E., 916
 Stumpf, V., 371
 Suenaga, K., 1722
 Sugihara, S., 204
 Suissa, S., 920
 Surwit, R.S., 1163
 Sussman, I., 974
 Sutherland, D.E.R., 1247
 Sweet, I.R., 1316

T

Taborsky, G.J., Jr., 723, 1157
 Tahara, Y., 81
 Tai, J., 383, 1129
 Tait, B.D., 926
 Takata, S., 1064
 Takata, Y., 653, 1397, 1515
 Takatsuki, K., 1633
 Takeda, J., 1583
 Takeshita, N., 702
 Täljedal, I.-B., 194
 Tamborlane, W.V., 901
 Taminato, T., 702
 Tanaka, A., 81
 Tanaka, S.-I., 1188
 Tani, S., 1173
 Tanimoto, M., 1633
 Tappy, L., 1212, 1708
 Tarsio, J.F., 532
 Tarui, S., 204, 342
 Taskinen, M.-R., 1271
 Tatemoto, K., 281
 Tattersall, R.B., 961
 Taylor, S.I., 982
 Tepler, J., 237
 Tessari, P., 512, 787
 Thirlby, R., 600
 Thivolet, C.H., 1279
 Thomas, J.W., 172
 Thomas, P.K., 714
 Thomsen, C., 760
 Thuesen, L., 851
 Tieche, J.-M., 441
 Tillil, H., 1195, 1351
 Timmers, K.I., 398
 Tokunaga, K., 342
 Tomera, J.F., 50
 Tomlinson, D.R., 488
 Tomlinson, M., 1689
 Torella, R., 1265
 Toyota, T., 1188
 Treutelaar, M.K., 499
 Triban, C., 1340
 Trovati, M., 780
 Truglia, J.A., 147
 Tsutsumi, C., 702
 Turk, J.W., 992, 1311
 Turtle, J.R., 359
 Tze, W.J., 383, 1129
 Tzur, R., 1618

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
 February, 137-255
 March, 257-365

April, 367-493
 May, 495-665
 June, 667-845

July, 847-1004
 August, 1005-1156
 September, 1157-1309

October, 1311-1448
 November, 1449-1590
 December, 1591-1726

AUTHOR INDEX 1988

U

Ullrich, A., 1071
Ulrichs, K., 321
Umpierrez, G.E., 371
Unger, R.H., 600
Usami, M., 702
Ushiyama, I., 1549

V

Valerio, A., 787
Van der Meide, P.H., 209
Van der Vliet, J.A., 1247
Van Heuven, W.A.J., 878
Vardi, P., 482
Varey, A.-M., 209
Vassali, P., 1082
Vega, G.L., 393
Venkatesan, N., 885
Vergani, D., 507, 1484
Vertommen, J.J., 471
Viberti, G.C., 507, 1641
Villanueva, G.B., 1103
Vinik, A.I., 334
Vinores, S.A., 1658
Viassara, H., 456
Voyles, N.R., 398
Vranic, M., 1025

W

Wales, J.K., 969
Wali, R.K., 104
Walker, M.D., 1509
Walker, R., 1301

Wallace, L.J., 949
Wallum, B.J., 723
Ward, W.K., 377, 723
Wardzala, L.J., 56
Warnock, G.L., 467
Warram, J.H., 1328
Wartofsky, L., 317
Watanabe, J., 1652
Watarai, T., 1397
Wegmann, D., 1444
Weir, G.C., 217, 232
Weitzner, G., 792, 920
Welsh, N., 1123, 1226
Wernett, D., 177, 185
Westman, J., 309
Wiedmeyer, H.-M., 60
Wilkin, T., 1392
Wilkins, S.D., 398
Willars, G.B., 488
Williams, E.H., 1658
Williams, G., 763
Williams, P.E., 749, 1531
Williamson, J.R., 1689
Wilson, G.L., 213, 1015
Witztum, J.L., 550
Wohlmann, H.J., 1652
Wolf, B.A., 992, 1311
Wolfe, R.R., 154
Wolfe-Lopez, D., 303
Wong, I., 1678
Wong, K.-Y., 1241
Wood, P., 1392
Worthen, S.M., 252
Wright, J.R., Jr., 112
Wright, K.S., 436
Wu, M.S., 1020
Wu, V.-Y., 1324

X

Xiang, H., 1358, 1542

Y

Yagi, S., 1064
Yagihashi, S., 544
Yagil, C., 800
Yale, J.-F., 327
Yamada, K., 204, 1583
Yamada, M., 1120
Yamamoto, M., 1064
Yamanaka, Y., 81
Yki-Järvinen, H., 1271
Yoneda, M., 1633
Yoon, J.-W., 989, 1053, 1287, 1722
Yoshimasa, Y., 1583
Yoshioka, S., 1549
Yoshioka, T., 204, 1549
Yost, T.J., 610
Young, A.A., 303
Young, L.H., 943
Young, N.L., 1151
Yue, D.K., 359

Z

Zaret, B.L., 943
Zawadzki, J.K., 154
Zawalich, K.C., 816, 1294, 1432, 1478
Zawalich, W.S., 137, 816, 1294, 1432, 1478
Zeidler, A., 824
Zhang, W.-X., 1129
Ziel, F.H., 166, 885
Zinman, B., 526

DIABETES: VOLUME 37 (1988) PAGE NUMBERS BY ISSUE

January, 1-136
February, 137-255
March, 257-365

April, 367-493
May, 495-665
June, 667-845

July, 847-1004
August, 1005-1156
September, 1157-1309

October, 1311-1448
November, 1449-1590
December, 1591-1726